Back to Search
Start Over
Commentary on "Prognosis according to the timing of recurrence in breast cancer" (Ann Surg Treat Res 2023;104:1-9).
- Source :
-
Annals of surgical treatment and research [Ann Surg Treat Res] 2024 Apr; Vol. 106 (4), pp. 237-238. Date of Electronic Publication: 2024 Mar 29. - Publication Year :
- 2024
-
Abstract
- Competing Interests: Conflict of Interest: Michael Gnant reports personal fees/travel support from Amgen, AstraZeneca, Daiichi Sankyo, Eli Lilly, Menarini-Stemline, MSD, Novartis, Pierre Fabre, Sandoz, Veracyte; an immediate family member is employed by Sandoz. No other potential conflicts of interest relevant to this article was reported.
Details
- Language :
- English
- ISSN :
- 2288-6575
- Volume :
- 106
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Annals of surgical treatment and research
- Publication Type :
- Academic Journal
- Accession number :
- 38586550
- Full Text :
- https://doi.org/10.4174/astr.2024.106.4.237